Inhibitors of HPPD such as nitisinone are used to treat patients with hereditary Tyrosinemia type 1 in which downstream metabolites of HPPD activity accumulate and are highly toxic to the kidney and liver (Mayorandan et al., 2014; Zeybek et al., 2015). Here, HPD is linked to Tyrosinemia type 1.